Posts Tagged: "due diligence"

Privacy and Data Security Due Diligence: Best Practices for Avoiding Bumps Down the Road

Privacy and data security issues can scuttle a deal or at least cost the parties a lot of money. For example, in the due diligence process involving the 2017 acquisition of Yahoo by Verizon, Yahoo disclosed two serious data breaches that compromised over a billion accounts. Yahoo had previously attempted to cover this up. The deal went ahead for nearly $4.5 billion but not before Verizon knocked $350 million off the transaction price and Yahoo paid over $100 million to settle SEC fraud charges and class action lawsuits.

Tales from the Trenches: Structuring IP and Technology Acquisitions

As we emerge from a global pandemic in which many businesses are mothballed or operating at limited capacity, we know that a great number will not survive. They will have to pivot or sell, whether asset-by-asset or entirely. Some will face fire sales, assignment for the benefit of creditors, or Chapter 7 or 11 processes supervised by the bankruptcy courts, or otherwise. It has never been more important to be thoughtful as a buyer or seller of intellectual property and technology.

Demystifying Legal Diligence in Tech Deals

You are about to strike a deal with an industry partner to develop an exciting new product. Or maybe you have identified the perfect opportunity to acquire an upstart company whose tech would allow you to expand into a lucrative market. Smart companies do their diligence and plan ahead to ensure they maximize the benefits and mitigate the risks of the deal. Fortunately, diligence into technology assets and intellectual property is not that different from the diligence you would do when buying a house. Not everyone is fluent in technology and intellectual property, though—these are complex areas with their own sets of issues. This article lays out five simple questions a company should ask itself throughout the diligence process to help tease out and navigate red flags, with the assistance of an experienced IP transactional attorney.

A Lack of Focus on Trade Secrets Can Pose Serious Risks

We all talk about the importance of data as business assets, but when it comes to buying and selling the companies that own them, we seem not to pay much attention. My anecdotal survey reveals that colleagues who focus on mergers and acquisitions  confess to a lack of focus on trade secrets. This may seem odd, even crazy, given the increasing percentage of industrial property represented by intangible assets—up from 17% in 1975 to 84% in 2015. The problem appears to start with the fact that secret information, no matter how central to the success of the business, is mysterious. Unlike the “registered rights” of patent, copyright and trademark, there are no government certificates defining secrets; and valuing them is hard. Add to that the imperative to get deals done faster and cheaper, and it’s easy to see how secrecy may have become the blind spot of transactional IP.

Freedom to Operate and the Interplay of Patent and Regulatory Exclusivity for Life Sciences

While part one of this two-part series on intellectual property (IP) due diligence focused on a life science company’s own IP portfolio, part two will address a company’s understanding of how it fits into the market by considering its freedom to operate, as well as its competitors’, and the interplay of patent and regulatory exclusivity as it relates to the company’s product. Patent and regulatory exclusivity—two areas that can provide the most value and protection to a life science product—are very interrelated. Simply identifying when a key patent naturally expires is not sufficient, because regulatory exclusivity could possibly extend the company’s ability to keep competitors off the market or allow competitors to speed up entry in certain situations.